Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INTERVIEW: Korea Initiative Aims To Create Global Clinical Trial Hub

This article was originally published in PharmAsia News

Executive Summary

In a recent interview with PharmAsia News, the head of the Korea Clinical Trial Global Initiative stressed the importance of continued government support in boosting the country’s competitiveness in clinical trials, amid narrowing gaps with its Asian rivals. He also talked about why the initiative is focusing on attracting early phase work from foreign firms and what South Korea needs to do to maintain its edge.

You may also be interested in...



Cell Therapies, Biosimilars Boost Biologics Clinical Trials In Korea

South Korean clinical trial data for 2016 reflects the global boom in biologics R&D and the decline in development of synthetic drugs. A series of clinical trial failures by major South Korean pharmaceutical firms may also have weakened overall drug development activities.

Asia Deal Watch: China Grand, ETheRNA Create mRNA Vaccine JV

Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.

Bukwang Speeds Lead Asset As It Eyes Danish Operation's Listing

Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.

Topics

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel